GU Cancers 2020 | CaboPoint: second-line cabozantinib for RCC

Laurence Albiges

Laurence Albiges, MD, PhD, Gustave Roussy Institute, Villejuif, France, discusses the CaboPoint trial (NCT03945773). This study focuses on cabozantinib as a second-line therapy for patients with clear cell metastatic renal cell carcinoma (RCC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter